Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$46 Mln
P/E Ratio
--
P/B Ratio
1.04
Industry P/E
--
Debt to Equity
0.52
ROE
-2.34 %
ROCE
-181.22 %
Div. Yield
0 %
Book Value
0.58
EPS
-2.95
CFO
$-360.12 Mln
EBITDA
$-448.80 Mln
Net Profit
$-479.92 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Sutro Biopharma (STRO)
| -56.34 | 4.76 | -59.22 | -78.69 | -51.29 | -40.39 | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
Sutro Biopharma (STRO)
| -56.81 | -46.91 | -45.70 | -31.46 | 97.36 | 21.95 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.73 | 9,808.03 | 20.22 | 23.13 | |
| 284.42 | 8,956.09 | 22.08 | 58.42 | |
| 26.83 | 9,559.25 | -- | -28.77 | |
| 103.38 | 10,030.35 | 30.81 | 14.16 |
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific... conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. Address: 111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 Read more
CEO & Director
Mr. William J. Newell J.D.
CEO & Director
Mr. William J. Newell J.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Sutro Biopharma (STRO) stood at $ 387 Mln as on 31-Dec-24
The share price of Sutro Biopharma (STRO) is $0.80 (NASDAQ) as of 23-Apr-2025 14:41 EDT. Sutro Biopharma (STRO) has given a return of -51.29% in the last 3 years.
Sutro Biopharma (STRO) has a market capitalisation of $ 46 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Sutro Biopharma (STRO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sutro Biopharma (STRO) and enter the required number of quantities and click on buy to purchase the shares of Sutro Biopharma (STRO).
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. Address: 111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
The CEO & director of Mr. William J. Newell J.D.. is Sutro Biopharma (STRO), and CFO & Sr. VP is Mr. William J. Newell J.D..
There is no promoter pledging in Sutro Biopharma (STRO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Sutro Biopharma (STRO) | Ratios |
|---|---|
|
Return on equity(%)
|
-234.19
|
|
Operating margin(%)
|
-312.73
|
|
Net Margin(%)
|
-366.62
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Sutro Biopharma (STRO) was $0 Mln.
$0.08
(
